Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer.

H Ozen1, M C Hall

  • 1Department of Urology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. ho02-k@tr-net.net.tr

Current Opinion in Oncology
|June 7, 2000
PubMed
Summary
This summary is machine-generated.

Developing reliable bladder cancer tumor markers is crucial. While promising urinary and molecular markers exist, none are widely used clinically, necessitating further validation for improved patient care and treatment selection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new adjacent tool in the management of clinical T1a solid renal masses.

Actas urologicas espanolas·2026
Same author

Neutrophil volume distribution width as a new marker in detecting inflammatory bowel disease activation.

International journal of laboratory hematology·2016
Same author

Successful outcome with second hematopoietic stem cell transplantation in a patient with IL-10R deficiency.

Bone marrow transplantation·2015
Same author

Is routine stenting necessary in pyeloplasty?

Pediatric surgery international·2013
Same author

Assessing symptom control in palliative home care.

Canadian family physician Medecin de famille canadien·2011
Same author

Can p53, Ki-67 and bcl-2 predict biochemical failure after radical prostatectomy?

Indian journal of urology : IJU : journal of the Urological Society of India·2010
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Urology
  • Oncology
  • Biomarker Research

Background:

  • Bladder cancer diagnosis and surveillance rely on invasive methods like cystoscopy and less sensitive urinary cytology.
  • There is a significant clinical need for accurate and noninvasive tumor markers for bladder cancer detection and management.

Purpose of the Study:

  • To review recent advancements in urinary and molecular tumor markers for bladder cancer.
  • To assess the potential of these markers in improving diagnostic accuracy, surveillance, and personalized treatment selection.

Main Methods:

  • Review of studies evaluating commercially available and experimental urinary markers (e.g., bladder tumor antigen, NMP22, telomerase, VEGF).
  • Examination of research on molecular prognostic markers (e.g., p53, p21) for bladder cancer.

Related Experiment Videos

  • Analysis of the clinical utility and limitations of current and emerging bladder cancer markers.

    • Main Results:

    • Several urinary markers show improved sensitivity over cytology but lack widespread clinical adoption.
    • Molecular markers like p53 and p21 are under investigation for predicting tumor behavior.
    • No novel markers have been integrated into routine clinical practice due to needs for standardization and validation.

    Conclusions:

    • Urinary and molecular markers hold promise for noninvasive bladder cancer diagnosis and personalized surveillance/treatment.
    • Further prospective, multicenter validation studies are essential to establish reproducibility and clinical confidence.
    • Rigorous evaluation is required before these markers can reliably guide clinical decisions in bladder cancer care.